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hMt-c-fos-LTR transgenic mice (U. R0ther, D. Komitowski, F. R. Schubert, and E. F. Wagner. Oncogene 4, 861-865, 1989) 
developed bone sarcomas in 20% (3/15) of females at 448 _+ 25 days and in 8% (1/12) of males at 523 days. After infection 
of newborns with Akv, an infectious retrovirus derived from the ecotropic provirus of the AKR mouse, 69% (20/28) of 
female animals and 83% (24/29) of males developed malignant fibrous-osseous tumors. The tumors in infected transgenics 
developed with higher frequency and a 200-days shorter mean tumor latency period. The hMt-c-fos-LTR transgene was 
expressed in all the fibrous-osseous tumors. They also showed newly integrated Akv.provirusee, but in most tumors Akv 
was detected and expressed in only a small number of the tumor cells. Wild-type C3H mice infected with Akv developed 
benign osteomas with an incidence of 33% and a latency period of 474 days. The data indicate that Akv exerts distinct 
pathogenic effects on the skeleton. In hMt-c-fos-LTR transgenic mice, predisposed to bone sarcomagenesis, Akv acts 
synergistically with the fos transgene, resulting in the development of fibrous-osseous tumors. © 1995 Academic Press, Inc. 
INTRODUCTION 
The Akv murine leukemia virus is derived from an en- 
dogenous provirus of the AKR mouse and belongs to a 
genus of related retroviruses (Chattopadhyay et aL, 1980; 
00ffin, 1990) which are essentially considered as non- 
pathogenic (Celander and Haseltine, 1984; Hays and 
Vredevoe, 1977; Lenz et aL, 1982; Lenz and Haseltine, 
1983; Nishizuka and Nakakuki, 1968; Pedersen et al., 
1981). Other ecotropic retroviruses derived from endoge- 
nous proviruses of BALB/c and C57/BL mice have been 
shown to harbor pathogenic potential in susceptible mice 
(Pedersen et aL, 1990; Schmidt et aL, 1988). Moreover, 
Akv X623 derived from the AKR mouse ecotropic provirus 
(LowyetaL, 1980)induces lymphomas (Speth etaL, 1995) 
as well as benign bone lesions (Luz et aL, 1991) after 
prolonged latency. A retroviral etiology of certain mouse 
bone tumors has been shown for FBJ MSV (Finkel eta/., 
1966) and FBR MSV (Finkel et aL,. 1975). These v-fos 
carrying retroviruses isolated from spontaneous and ra- 
diation-induced osteosarcomas are highly oncogenic for 
skeletal cells both in v/vo (Michiels et aL, 1984; Ward 
and Young, 1976) and in tissue cultures of mandibular 
0ondyles (Schmidt et aL, 1986). 
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A large body of data on the biological effect of c-fos 
(see references in Grigoriadis et al., 1993) suggests that 
the fos protooncogene plays a pivotal role in the regula- 
tion of differentiation and proliferation (Angel and Karin, 
1991; Bravo, 1990; Curran, 1988), as well as in mouse 
(SchOn et al., 1986) and human (Wu et aL, 1990) skeletal 
neoplasia. This notion is supported by osteosarcoma de- 
velopment in c-fos transgenic mice (Grigoriadis et al., 
1993; Rflther et al., 1989), and chondrosarcoma develop- 
ment in c-fos chimaeric mice (Wang et aL, 1992). Given 
the transforming potential of the fos gene product, it 
might be expected that hMt-c-fos-LTR transgenic mice 
would be highly susceptible to osteosarcoma develop- 
ment, but only 18% of mice develop tumors (R0ther etaL, 
1989). The low incidence of osteosarcomas in hMt-c-fos- 
LTR transgenic mice suggests that genetic factors in 
addition to c-fos are necessary for bone tumor devel- 
opment. 
Previous observations on cell lines established from 
osteosarcomas of hMt-c-fos-LTR transgenic mice (Go- 
ralczyk etaL, 1990) indicated that in bone neoplasia there 
may be a cooperation between activated endogenous 
retroviruses and c-fos. We observed high expression of 
endogenous retroviruses in these tumor cell lines, but 
not in cell lines established from normal tissues of hMt- 
c-fos-LTR transgenic mice (unpublished data). In order 
to test whether activated endogenous retroviruses coop- 
erate with the fos oncogene in skeletal neoplasia we 
infected newborn hMt-c-fos-LTR transgenic mice with 
Akv, a retrovirus derived from the ecotropic provirus of 
the AKR mouse (Lowy et al., 1980). Compared to nonin- 
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fected transgenic controls, infected hMt-c-fos-LTR 
transgenic mice showed significantly increased bone tu- 
mor incidence and a considerably shortened tumor la- 
tency period. Thus it seems that activated endogenous 
retroviruses and the fos oncogene cooperate in bone 
neoplasia. 
MATERIALS AND METHODS 
Mice 
hMt-c-fos-LTR transgenic C3H/HeJ mice (RQther et aL, 
1987) were mated to C3H/He/R1/Nhg mice from the 
breeding colony of the GSF. Newborn offspring were 
infected with Akv as described (Speth et aL, 1995). Mice 
were killed, X-rayed, and autopsied when they showed 
illness or tumor development or at the end of the experi- 
ment (586 to 599 days in Akv-infected transgenics; 711 
to 716 clays in noninfected transgenios). The bone tumors 
were diagnosed roentgenographically and in part histo- 
logically after staining with H&E and with von Gieson 
stain. The definition "bone tumors" included all expan- 
sively growing neoplasms containing newly formed bone 
as well as bone neoplasms described by RQther et aL 
(1989). All other tumors were diagnosed as described 
(Schmidt et aL, 1984). For statistical evaluation we used 
Fisher's exact test and the log rank test. 
Tumor transplantation 
Transplantability of bone tumors was determined by 
subcutaneous implantation of primary Akv-induced tumor 
tissue into syngeneic newborn wild-type C3H mice. The 
mice were killed when the transplant tumors reached 
10 mm. The tumors were diagnosed and processed as 
above. 
DNA blot analysis 
High-molecular-weight DNA was isolated from the tu- 
mors, digested with the appropriate restriction endonu- 
cleases, and analyzed by Southern blotting. Ten micro- 
grams of restriction enzyme-digested cellular DNA was 
separated on 1% agarose gels, transferred to Zeta probe- 
GT membranes (Bio-Rad), and probed with 32p-labeled 
probes. Hybridizations and washings were performed as 
described (Church and Gilbert, 1984). Proviral integration 
of Akv was detected by EcoRI digestion of tumor DNA 
and hybridization of the filters with an ecotropic virus- 
specific probe (Chattopadhyay et aL, 1980). Control tis- 
sues included spleen from uninfected hMt-c-fos-LTR 
transgenic C3H/HeJ mice, three liver adenomas from 
hMt-c-fos-LTR transgenic and normal C3H/HeJ mice, four 
malignant lymphomas from normal C3H/HeJ mice, and 
normal spleen tissues from Akv-infected hMt-c-fos-LTR 
transgenic, bone tumor-bearing mice. The transgene was 
detected by digestion with EcoRI, EcoRV, and Kpnl and 
hybridizing with a v-fos specific probe (Curran, 1988). 
PCR analysis of DNA 
Figure 1 shows the strategy used to distinguish Akv 
sequences from the closely related C3H mouse endoge- 
nous provirus emv-1. One PCR primer in each of the two 
pairs (Akv-1 and Akv-4) recognizes the two 99-bp repeat 
junction present in the LI3 region of Akv LTR. The second 
primer in each of the two pairs (Akv-2, Akv-3) recognizes 
sequences homologous to the C3H provirus. Akv-1 and 
Akv-2 primers amplify a 285-bp region. Akv-3 and Akv-4 
primers amplify a 449-bp Akv-env fragment. The primers 
Akv-8 and Akv-9 amplify a 382-bp fragment in the C3H 
provirus and a 481-bp fragment in Akv. This primer set 
and a pAkv-CAT plasmid containing an Akv LTR region 
were used to generate an Akv LTR probe. 
PCR was performed on Gen Amp PCR system 9600 
(Perkin Elmer). The initial cycle of 94 ° for 1 min, 65 ° for 
1 min 30 sec,.72 ° for 2 min was followed by 28 cycles 
of 94 ° for 24 sec, 65 ° for 2 min, 72 ° for 2 min and by 
an elongation step at 72 ° for 10 min. The amplification 
temperature for a control actin PCR was 60 °. Ten microli- 
ters of PCR product was separated on a 2% agarose gel, 
visualized with ethidium bromide, blotted to Zeta probe- 
GT membranes (Bio-Rad) by electroblotting, and hybrid- 
ized with random primer-labeled probes. Nucleotide se- 
quencing was performed using the Automated Laser Flu- 
orescent DNA sequencing system 373A (Applied Biosys- 
terns) protocols for ABI dye terminator cycle sequencing. 
RT PeR 
Total cellular RNA was reverse transcribed into cDNA 
and used as template for PCR. Random hexanucleotides 
were used as primers for reverse transcription; 0.5 #g of 
total RNA was centrifuged (10,000 rpm, 30 min), lyophi- 
lized, dissolved in 20 /~1 water, and treated with DEPC. 
The RNAwas heated (68 °, 10 min) to denature its second- 
ary structure and chilled; 100/~1 reaction mix (1 X PCR 
reaction buffer, (Perkin Elmer Cetus), 100 #1 each of 
dGDP, dCTP, d-i-FP, and dATP (Pharmacia), and 10 U 
RNasin (Promega, 40 U/#I, 5 U AMV reverse tran- 
scriptase (Boehringer, 24 U/#I), 5 #g hexanucleotides 
(Pharmacia) and sterile water) were added and the reac- 
tion was stopped by freezing the tubes at -20 ° . 
Hot start PCR (D'Aquila et al., 1991) was performed 
(Thermocycler 480, Perkin Elmer Cetus) for amplification 
of the transcripts from the integrated Akv and the hMt- 
c-fos-LTR transgene. The reaction mix contained 1 X 
POR reacting buffer, 100 #M each dNTP, 1 #M each 
primer, and 2.5 U Taq polymerase (Perkin Elmer Cetus), 
The initial cycle of 94 ° for 2 min, 60 ° for 2 min, and 72 ° 
for 2 min was followed by 35 cycles for the transgene 
and 26 cycles for Akv in which the denaturation step at 
94 ° was shortened to 1 min. The final elongation reaction 
was at 72 ° for 10 min. PCR products were electropho- 
resed on a 2% agarose gel and transferred to Zeta-Probe 
membranes (Bio-Rad). Akv transcripts were hybridized 
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FIG. 1. Strategy for detection of Akv sequences in hMt-c-fos-LTR transgenic C3H mice carrying the emv-1 ecotropic provirus. PCR primers were 
targeted to the Akv-specific 99-bp repeat in the U3 region of the LTR (Etzerodt et aL, 1984). The location of the ecotropic-specific virus probe 
delimited by two Smal (S) sites in the env gene of Akv (base No. 5748-6076) is indicated on the Akv genomic map. The enlarged region underneath 
encompasses the 3' part of the Akv p15E gene and the 3' LTR. Distinctive restriction sites in this region are Pstl (P), EcoRV (E), Apal (A), Avail 
(Av), and Sau3A (Sa). Primer pair Akv-1 and Akv-2, giving a 285-bp product, was used for amplification of the Akv-U3 region; primer pair Akv-3 and 
Akv-4, giving a 449-bp product, was used to amplify the 5' portion of the U3 region and part of p15E. Primers Akv-1 and Akv-4 are homologous to 
the 99-bp repeat junction which is characteristic of the Akv LTR. Primer pair Akv-8 and Akv-9 are homologous to the U3 and R regions of most 
ec0tropic retroviruses and have been used to generate hybridization probes by PCR amplification of an Akv-LTR region from a plasmid. The Akv 
specificity of the PCR primers was demonstrated by the absence of Akv-related sequences in PCR products from DNAs isolated from six different 
03H/HeJ mice (Fig. 3, lane C3H) and the presence of a PCR product with/~-actin primers (data not shown). To exclude an inhibitory effect of C3H 
DNAs on Akv-PCR, C3H DNA was mixed in a 1,1 ratio with DNA of tumors shown to contain Akv sequences, and the DNA mixtures were used as 
template inPCRs with primers Akv-1 and Akv-2 (see Fig. 3, lanes 85, 85 + CSH and C3H). Akv-U3 (285 bP) PCR primers, Akv-1 (5') CCCCAGAAACAG- 
AGAGGC; Akv-2 (3') GCGCGCCGAGTGTGG. Akv-env (449 bp) PCR primers, Akv-3 (5') GTCCCCTTGGqq-CACCAACC; Akv-4 (3') GCCTCTCTGqqq-CTG- 
GGGACC Akv-ecotropic U3 (Akv: 481 bp), (C3H provirus, 381 bp) PCR primers, Akv-8 (5') CAGCTAAOTGCAGTAACGCCAT; Akv-9 (3') CGACTCAGT- 
0TATOGGAGGACT. 
with the PCR-amplified Akv-3/Akv-4 fragment (Fig. 1). 
PCR products were characterized by restriction analysis 
as well as by direct sequencing of PCR products of se- 
lected tumors. The fos-PCR product was confirmed by 
hybridization to a 3Zp-labeled v-fos probe. 
RESULTS 
Akv enhances bone tumor  deve lopment  in hMt-c-fos- 
LTR transgenic mice 
Untreated hMT-c-fos-LTR transgenic C3H mice were 
observed for up to 716 days (Table 1). Twenty percent 
of females and 8% of males developed single bone tu- 
mors after a mean latency period of 448 and 623 days, 
respectively. After infection of newborn hMt-c-fos-LTR 
transgenic mice with Akv, a total of 76% of the mice 
developed fibrous-osseous tumors with a mean tumor 
latency of 274 days. In females tumor incidence was 69% 
with a mean of 3.1 tumors per tumor-bearing mouse; in 
males tumor incidence was 83% with a mean of 4 tumors 
per tumor-bearing mouse. Akv-infected wild-type C3H 
mice developed osteomas with an incidence of up to 
33% and a mean latency of 477 days. No bone tumors 
were detected in 35 control C3H mice within a 702-day 
observation period. In other studies 199 female control 
C3H mice included in a 4-year genetic monitoring pro- 
gram developed 3 (1.5%) bone tumors after a latency 
period of 21 years. 
The majority of the bone tumors observed in the Akv- 
infected hMt-c-fos-LTR transgenic mice were fibrous-os- 
seous tumors. In addition to these, we also detected 2 
mice with osteomas. In the Akv-infected wild-type C3H 
mice all bone tumors were diagnosed as osteomas, a 
benign, expansively growing bone tumor characterized 
by a smooth outline and compact bone. Tumor tissue of 
an Akv-induced f ibrous-osseous bone tumor gave rise to 
a continuous line of osteogenic transplant tumors after 
transplantation indicating its malignancy. Four out of 54 
Akv-infected transgenic mice developed lymphomas and 
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TABLE 1 
ENHANCEMENT OF BONE TUMORIGENESIS IN hMt-c-fos-LTR TRANSGENIC C3H MICE WITH Akv 
Bone tumor incidence 
No. of Mean latency period Observation 
Mice mice Females Males (days, f/m) ~ period (days) 
Wild type 35 0% (0/23) 0% (0/12) 702-716 
Akv-infected wild type 17 33% (6/18) 13% (1/8) 477 b 536-544 
hMT-c-fos-LTR 27 20% ° (3/15) 8% ~ (1/12) 448 _+ 25/523 711-716 
Akv-infected hMT-c-fos-LTR 57 69% e (20/28) 83% f (24/29) 268 + 122/279 _+ 109 686-592 
Note. The data show tumor incidence at D y 600 of the experiment unless otherwise noted. The tumors were diagnosed by X-ray and by 
histological sections after staining with H&E and von Gieson. 
The mean latency period was calculated over the entire observation period; f, f males; m, males. 
b Mean latency period of osteomas in three mice which were detected before the nd of the observation period. 
c Two additional female mice with single tumors were observed on Days 700 and 714.' 
dThree additional male mice with a mean of 1.3 tumors per mouse were observed on Days 603, 609, and 713. 
e p = 0.001, Fisher's exact test, compared to noninfected females; P < 0.0001, log rank test for the entire observation period compared to 
noninfected females. 
~P = 0.000003, Fisher's exact est, compared to noninfected males; P < 0.0001, log rank test for the entire observation period compared to 
noninfected males. 
2 developed liver adenomas. In conclusion, Akv infection 
significantly enhanced bone tumor development and 
shortened the tumor latency period by about 200 days 
in hMt-c-fos-LTR transgenic mice. 
c-fos is expressed in the majority of the bone tumors 
The presence of the c-fos transgene in genomic DNA 
from 24 randomly selected tumors of Akv-infected hMt-c- 
fos-LTR transgenic mice was confirmed by EcoRI, EcoRV, 
and Kpnl digestion of tumor DNA, Southern blotting, and 
hybridizing with a v-fos probe, Neither the transgene nor 
the endogenous c-fos fragments were altered. The ex- 
pression of the transgene was shown by RT-PCR from 
tumor RNA using primers spanning c-fos and p15E se- 
quences of the vector, An 890-bp RT-PCR product which 
hybridized with the v-los probe was detected in 21 out 
of 24 (87%) bone tumors. Northern blot analysis of bone 
tumors showed varying amounts of fos mRNA without 
correlation between the mRNA levels and other tumor 
features. The 890-bp RT-PCR product was not found in 
RNA isolated from the normal liver of a noninfected hMt- 
c-fos-LTR transgenic mouse with an osteogenic tumor, 
or in nontransgenic control mice. 
Proviral Akv is not present in all tumor cells 
DNAs from 24 f ibrous-osseous tumors, 3 lymphomas, 
and 3 liver tumors from infected mice were analyzed for 
the presence of Akv sequences. Digestion with EcoRI 
showed the endogenous ecotropic provirus (emv-1) of 
C3H/HeJ mice on an approximately 18-kb restriction frag- 
ment (Jenkins et a/., 1982). Fourteen out of 24 showed 
additional ecotropic provirus sequences on Southern 
blots. In 6 out of these 14 tumors (Nos. 67, 78, 84, 85,91, 
95) the intensity of the signals suggested the presence of 
a provirus in most of the tumor cells, indicating clonal 
growth of virus-infected cells. In 8 out of 24 tumors (Nos. 
63, 70, 73, 75, 77, 79, 90, 92) new proviruses Were present 
in a small proportion of tumor cells. No additional proviraL 
62 63 65 
23-  
9 -  
bone tumors  lymphoma 
66 67 68 70 72 73 75 76 78 77 79 83 84 85 86 90 91 92 93 94 95 81 87 88 
l iver  tumors  
80 89  96 
- 23 
-9  
FIG. 2. Southern blot analysis of tumor DNAs from Akv-infected hM -c-fos-LTR transgenic mice. High-molecular-weight DNAs were digested with 
EeoRi, and the restriction fragments were eleetrophoresed, blotted, and probed with the ecotropic retrovirus-specific probe. The DNAs are derived 
from fibrous-osseous (bone) tumors, lymphomas, and liver tumors. Molecular size markers are indicated in kilobases. The numbers refer to individual 
tumors as in Figs. 3 and 4. 
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FIG. 3. PCR analysis showing the presence of Akv sequences in tumor DNAs. PCR-U3, PCR amplification of a 285-bp Akv U3 sequence with Akv- 
1 and Akv-2 primers in tumors and control cells from Akv-infected transgenic 03H mice. 85, fibrous-osseous tumor; 85 + C3H, C3H DNA mixed 
(1,1) with 85-DNA; C3H, C3H genomic DNA; NMRI and NMRI-Akv, genomic DNA of noninfected and Akv-infected NMRI mice; La, liver tumor, and 
Ly, lymphoma, in bone tumor bearing mice. POR-env, PCR amplification of a 449-bp Akv env sequence with Akv-3 and Akv-4 primers in tumors and 
control cells from Akvdnfected hMt-c-fos-LTR transgenic 03H mice. C3H, genomic DNA from a C3H mouse; NIH3T3-Akv and NIH3T3, DNA from 
Akv-infected NIH3T3 and noninfected NIH3T3 cells; the numbers refer to fibrous-osseous tumors; La, liver tumor; 86-, 92-, 93-spleen, spleen cells 
from bone tumor-bearing mice; Ly, lymphoma. 
sequences were detected by Southern analysis in the 
other 10 tumors (Fig. 2). The lymphomas in Akv-infected 
transgenic mice contained several roughly equimolar 
signals from newly acquired ecotropic proviruses. No 
additional proviruses were found in liver adenomas, a 
tumor which also appears spontaneously in wild-type 
c3m mice (Fig. 2), in lymphomas from control mice, in 
normal spleens from bone tumor-bearing Akv-infected 
transgenic mice, and in spleens from noninfected 
transgenic controls (data not shown). 
Southern blot analysis could not discriminate between 
newly integrated Akv proviruses and potentially activated 
and reintegrated endogenous ecotropic provirus from the 
emv-1 locus. To identify newly integrated proviruses and 
to check for the presence of Akv in Southern blot-nega- 
tive tumors we subjected tumor DNAs to PCR analysis. 
Akv specific primers were used which allowed discrimi- 
nation of newly integrated Akv from the endogenous eco- 
tropic provirus emv-1 of C3H mice (Fig. 1). The primer 
pairs Akv-1/Akv-2 and Akv-3/Akv-4 detected Akv se- 
quences in DNAs of all tumors from Akv-infected hMt-c- 
f0s-LTR transgenic mice (Fig. 3). The sequence homology 
to Akv was confirmed by direct sequencing of HPLO- 
purified DNAs of three randomly selected PCR products 
(data not shown). 
To correlate the different results obtained by Southern 
bl0t (Fig. 2) and PCR analyses (Fig. 3), we quantified 
the PCR analysis by varying the number of amplification 
cycles. DNA from tumors showing multiple Akv se- 
quences on Southern blots (85, 95, 87), generated the 
characteristic Akv env band of 449 bp after 19 cycles. 
DNA from tumors showing either a weak (70, 79, 83) or 
no (89) Akv env signal on Southern blots generated a 
band of similar intensity only after 21-23 and 26 PCR 
cycles (not shown). These data indicate that the results 
obtained by quantitative PCR are compatible with the 
results from Southern blot analysis. Thus Akv was pres- 
ent in all tumors, but in about 40% of the fibrous-osseous 
tumors Akv provirus was present only in a small cell 
population. 
Akv is expressed in the osteogenic tumors 
Akv env gene transcripts were detected by PCR ampli- 
fication of reverse-transcribed total cellular RNA (RT- 
PCR) in all but two osteogenic tumors, in two out of 
three lymphomas, and in two out of the three liver tumors 
analyzed. Representative data are shown in Fig. 4. Integ- 
rity of the RNAs was confirmed by amplification of the 
POR-negative RNAs using primers for ~-actin (not 
shown). These results showed that the sequences span- 
ning the Akv env and LTR/U3 (bp 7593-8042) region 
were expressed, although at a low level, in virtually all the 
fibrous-osseous tumors which developed in Akv-infected 
hMt-c-fos-LTR transgenic C3H mice. 
RT-PCR..env 
- 44g  
FIG. 4. RT-PCR analysis with total cellular RNA of tumors from Akv- 
infected bMt-c-fos-LTR transgenic and nontransgenic ontrol mice. The 
449-bp product was generated by use of the Akv-env primer pair Akv- 
3 and Akv-4 and probed with the PCR product of an Akv LTR-containing 
plasmid by use of Akv-8 and Akv-9 primers. The data show representa- 
tive fibrous-osseous tumors; 89-La, liver tumor; 81-Ly, lymphoma; Li, 
liver DNA from an hMt-c-fos-LTR transgenic mouse. 
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DISCUSSION 
In this paper we describe the influence of Akv, a retro- 
virus derived from the endogenous ecotropic provirus of 
the AKR mouse (Lowy etaL, t980), on c-fos-induced bone 
tumor development in hMt-c-fos-LTR transgenic mice. 
The results show that infection of hMt-c-fos-LTR mice 
with Akv increases the bone tumor incidence and short- 
ens the tumor latency period. 
The data suggest that Akv and c-fos act synergistically 
to enhance the oncogenic process in the skeleton. The 
effect of Akv on wild-type C3H mice differed markedly 
from the effect on the hMt-c-fos-LTR transgenic mice. 
Thirty-three percent of the infected wild-type mice devel- 
oped benign osteomas, whereas 76% of transgenic mice 
developed malignant bone tumors exhibiting a character- 
istic trabecular bone pattern together with fibrous tissue. 
Only 4% of the infected transgenics developed benign 
osteomas. Fibrous-osseous tumors and osteomas could 
be clearly differentiated by X-ray and histological analy- 
sis (Luz et al., 1991). The appearance of malignant umors 
in hMt-c-fos-LTR transgenic mice after Akv infection, and 
the drop of osteoma incidence from 33% in Akv-infected 
wild-type mice to 4% in Akv-infected transgenic mice, 
indicates a coupling of the biological activities of Akv 
and c-fos (Luz etaL, 1991; Ruddle eta/., 1993; RQther et 
aL, 1987; Schmidt eta/., 1988). 
Earlier reports indicating a nonpathogenic nature of 
Akv probably resulted from the shorter observation peri- 
ods used (Celander and Haseltine, 1984; Hays and 
Vredevoe, 1977; Lenz et aL, 1982; Lenz and Haseltine, 
1983; Nishizuka and Nakakuki, 1986; Pedersen et al., 
1981). Extension of the observation period for Akv-in- 
fected mice for up to 700 days postinfection clearly 
shows the leukemogenic (Speth et aL, 1995) and bone 
pathogenic (Luz et a/., 1991) potential of this virus in 
different strains of mice. 
In contrast to Moloney MuLV-induced lymphomagen- 
esis (Corcoran eta/., 1984; Tsichlis and Lazo, 1991; van 
Lohuizen et aL, 1991, 1989), the underlying mechanism 
of Akv pathogenicity is not yet clear (Kung et a/., 1991). 
One out of 24 Akv-induced bone tumors contained an 
additional 4.8-kb fragment, as detected by hybridization 
of Kpnl-digested DNA hybridized with a bmi-1 specific 
probe. No alterations were found after hybridization with 
a fos probe or with an mlvi-1 probe (not shown). The 
p53 locus, although frequently altered in other tumors 
(Strauss et a/., 1992) and recently identified as a target 
for ETn insertion in radiation-induced osteosarcoma (Mi- 
treiter et al., 1994), was not rearranged in any of 24 bone 
tumors. Neither were the DNAs from liver adenomas or 
lymphomas rearranged in the p63 (Mowat et al., 1985; 
Wolf and Rotter, 1984), mlvi-1 (Tsichlis and Lazo, 1991; 
Tsichlis etaL, 1983), or bmi-1 (Berns, 1991; van Lohuizen 
et aL, 1991) loci. These data do not rule out Akv integra- 
tion into other relevant arget sites; however, the absence 
of common bands on the Southern blots and the morpho- 
logical characteristics of the fibrous-osseous tumors 
suggest a synergism between Akv and the fos oncogene 
in bone tumorigenesis. This synergistic activity results in 
the appearance of a bone tumor which looks morphologi- 
cally more benign than the bone tumors in noninfected 
c-fos transgenic mice (RQther et al., 1989) but revealed 
the pathogenic potential of c-fos-induced osteosarcomas 
(Goralczyk et al., 1990). 
Recombinant viruses between Akv and endogenous 
nonecotropic proviruses (DiFronzo and Holland, 1993; 
Lung eta/., 1983; Stoye et a/., 1991) were only found in 
1 out of 24 tumors by Southern blotting and hybridizing 
with an MCF-1 probe (Chattopadhyay et aL, 1982) (data 
not showo). Moreover, the low lymphoma incidence was 
only 7% in Akv-infected mice. These data indicate that 
MOF type viruses do not play a key role in Akv-induced 
bone tumors. - 
In the majority of the tumors Akv provirus was present 
in only a small number of the tumor cells. This finding is 
surprising and, together with the morphological appear- 
ance of the fibrous-osseous tumors, points toward a par- 
ticular role for replication-competent, slow-transforming 
retroviruses in bone neoplasia (Pedersen eta/., 1990; 
Schmidt et aL, 1984, 1988). The presence of irregular 
bone within the well differentiated tumors is compatible 
with expression of Akv in a few distinct areas of the 
tumors, and also with the direct correlation between the 
steady state levels of Akv mRNA and the size of the 
tumors (data not shown here). Emv-1 provirus expression 
could be ruled out by PCR analysis and seemed not to 
be involved in the tumorigenic processes. 
From our data we hypothesize that expression of an 
Akv-encoded protein and its binding to a heterologous, 
bone cell-specific receptor may enhance cell growth as 
described for SFFV gp55 and the erythropoietin receptor 
(Li et aL, 1990). Similarly, a virus-induced, locally acting 
factor may exert mitotic and/or differentiation-inducing 
activity in virus-infected cells of the osteoblastic lineage. 
Such a mechanism has been observed following HTLV- 
1 infection (Motokura et aL, 1988; Watanabe et al., 1990) 
and suggested in HTLV-1 LTR-tax transgenic mice (Rud- 
die etaL, 1993). Possible effector molecules with a direct 
effect upon cells of the skeleton may include the proto- 
oncogene c-fos (Nagata et aL, 1989), parathyroid hor- 
mone-related peptide (PTHrP) (Motokura et aL, 1988; Wa- 
tanabe eta/.,  1990), transcription factors (Paul et al., 
1990), cytokines (Tschachler et al., 1989) and their recep- 
tors (Inoue etaL, 1986), or both (Green etaL, 1989; Maruy- 
ama eta/., 1987; Siekewitz et aL, 1987). 
As in c-fos-transgenic and c-fos-chimaeric mice 
(RQther et aL, 1987, 1989; Grigoriadis et aL, 1993; Wang 
et aL, 1992), the time of onset of the initiating event in 
bone tumorigenesis seems crucial to the tumor phen0- 
type. In C3H strain mice spontaneous provirus expres- 
sion appears after adolescence with a low incidence, 
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resulting in a relatively small number of tumors and 
allowing the c-fos transgene to determine the tumor phe- 
n0type. In the experiments described here, Akv was in- 
jected at birth and followed by early viremia, exerting its 
biological activity at an earlier developmental stage of 
the skeleton. This allows cooperating events to ensue 
and a distinct tumor to develop. 
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